Search

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track

Michiel van den Berg sheds light on the challenges and opportunities facing the industry as it adapts to new materials and regulatory requirements

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

From cybersecurity challenges and AI-driven decision-making, to making mundane tasks more skillful, robotics is reshaping pharmaceutical operations.

Purdue University’s Young Institute is tackling pharma’s toughest challenges— from mRNA stability to aseptic manufacturing.

Manufacturing bottlenecks remain a key hurdle in CAR-T therapy. Can automation and digital integration change that?

We get the story behind the development of Spiroligomer molecules and how they can help drug the undruggable.

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

From geopolitical conflicts to cyber threats, CDMOs must rethink resilience.

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report